The Effects of Vitamin D Supplementation on Musculoskeletal Health: The VITAL and DO-Health Trials
The Journals of Gerontology: Series A · 2023
DOI: 10.1093/gerona/glad073 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journals of Gerontology: Series A, 2023. Verfasst von Meryl S LeBoff und 1 weiteren Autor:innen. Beteiligte Einrichtung: Calcium and Bone Section, Skeletal Health and Osteoporosis Center and Bone Density Unit, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Fractures, Bone, Osteoporosis, Vitamin D Deficiency. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NCI NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Previous clinical trials and systematic reviews on the effects of supplemental vitamin D on musculoskeletal outcomes are conflicting. In this paper, we review the literature and summarize the effects of a high daily dose of 2 000 IU vitamin D on musculoskeletal outcomes in generally healthy adults, in men (≥50 years) and women (≥55 years) in the 5.3-year US VITamin D and OmegA-3 TriaL (VITAL) trial (n = 25 871) and women and men (≥70 years) in the 3-year European DO-HEALTH trial (n = 2 157). These studies found no benefit of 2 000 IU/d of supplemental vitamin D on nonvertebral fractures, falls, functional decline, or frailty. In VITAL, supplementation with 2 000 IU/d of vitamin D did not reduce the risk of total or hip fractures. In a subcohort of VITAL, supplemental vitamin D did not improve bone density or structure (n = 771) or physical performance measures (n = 1 054). In DO-HEALTH, which investigated additive benefits of vitamin D with omega-3 and a simple home exercise program, the 3 treatments combined showed a significant 39% decreased odds of becoming prefrail compared to the control. The mean baseline 25(OH)D levels were 30.7 ± 10 ng/mL in VITAL and 22.4 ± 8.0 ng/mL in DO-HEALTH and increased to 41.2 ng/mL and 37.6 ng/mL in the vitamin D treatment groups, respectively. In generally healthy and vitamin D-replete older adults not preselected for vitamin D deficiency or low bone mass or osteoporosis, 2 000 IU/d of vitamin D had no musculoskeletal health benefits. These findings may not apply to individuals with very low 25(OH)D levels, gastrointestinal disorders causing malabsorption, or those with osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Calcium and Bone Section, Skeletal Health and Osteoporosis Center and Bone Density Unit, Harvard Medical School, Boston, Massachusetts, USA.
- Endocrinology, Diabetes and Hypertension Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Geriatrics and Aging Research, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
ORCID-Profile: Heike A Bischoff-Ferrari
Förderung
- NIA NIH HHS
- NCI NIH HHS
- NIAMS NIH HHS
- NINDS NIH HHS
- NIH HHS
- NHLBI NIH HHS
- NCCIH NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
LeBoff, M. S., & Bischoff-Ferrari, H. A. (2023). The Effects of Vitamin D Supplementation on Musculoskeletal Health: The VITAL and DO-Health Trials. The Journals of Gerontology: Series A. https://doi.org/10.1093/gerona/glad073
Vancouver
LeBoff MS, Bischoff-Ferrari HA. The Effects of Vitamin D Supplementation on Musculoskeletal Health: The VITAL and DO-Health Trials. The Journals of Gerontology: Series A. 2023. doi:10.1093/gerona/glad073
BibTeX
@article{LeBoff2023,
author = {LeBoff, Meryl S and Bischoff-Ferrari, Heike A},
title = {The Effects of Vitamin D Supplementation on Musculoskeletal Health: The VITAL and DO-Health Trials},
journal = {The Journals of Gerontology: Series A},
year = {2023},
doi = {10.1093/gerona/glad073}
}
EUVIMED